Trial Profile
A randomised, double-blind, placebo-controlled proof-of concept study of the efficacy of gevokizumab 60mg subcutaneously every 4 weeks over 24 weeks in the treatment of patients with polymyositis, dermatomyositis or necrotizing autoimmune myopathy disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Feb 2018
Price :
$35
*
At a glance
- Drugs Gevokizumab (Primary)
- Indications Dermatomyositis; Myositis
- Focus Biomarker; Proof of concept; Therapeutic Use
- Sponsors IRIS
- 14 Mar 2016 Status changed from recruiting to completed, according to United Kingdom Clinical Research Network record.
- 10 Apr 2014 New trial record